|
1
|
Okegawa T, Pong RC, Li Y and Hsieh JT: The
role of cell adhesion molecule in cancer progression and its
application in cancer therapy. Acta Biochim Pol. 51:445–457. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petruzzelli L, Takami M and Humes HD:
Structure and function of cell adhesion molecules. Am J Med.
106:467–476. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maheshwari G, Brown G, Lauffenburger DA,
Wells A and Griffith LG: Cell adhesion and motility depend on
nanoscale RGD clustering. J Cell Sci. 113:1677–1686.
2000.PubMed/NCBI
|
|
4
|
Trzpis M, McLaughlin PM, de Leij LM and
Harmsen MC: Epithelial cell adhesion molecule: More than a
carcinoma marker and adhesion molecule. Am J Pathol. 171:386–395.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herlyn M, Steplewski Z, Herlyn D and
Koprowski H: Colorectal carcinoma-specific antigen: Detection by
means of monoclonal antibodies. Proc Natl Acad Sci USA.
76:1438–1442. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Imrich S, Hachmeister M and Gires O: EpCAM
and its potential role in tumor-initiating cells. Cell Adhes Migr.
6:30–38. 2012. View Article : Google Scholar
|
|
7
|
Litvinov SV, Velders MP, Bakker HA,
Fleuren GJ and Warnaar SO: Ep-CAM: A human epithelial antigen is a
homophilic cell-cell adhesion molecule. J Cell Biol. 125:437–446.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maetzel D, Denzel S, Mack B, Canis M, Went
P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, et al: Nuclear
signalling by tumour-associated antigen EpCAM. Nat Cell Biol.
11:162–171. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sen S and Carnelio S: Expression of
epithelial cell adhesion molecule (EpCAM) in oral squamous cell
carcinoma. Histopathology. 68:897–904. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baeuerle PA and Gires O: EpCAM (CD326)
finding its role in cancer. Br J Cancer. 96:417–423. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Went P, Vasei M, Bubendorf L, Terracciano
L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G and Baeuerle
PA: Frequent high-level expression of the immunotherapeutic target
Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer.
94:128–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wolpin BM, Meyerhardt JA, Mamon HJ and
Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J
Clin. 57:168–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Longo WE and Johnson FE: The preoperative
assessment and postoperative surveillance of patients with colon
and rectal cancer. Surg Clin North Am. 82:1091–1108. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Connell MJ, Colangelo LH, Beart RW,
Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC,
Ryan DP, et al: Capecitabine and oxaliplatin in the preoperative
multimodality treatment of rectal cancer: Surgical end points from
National Surgical Adjuvant Breast and Bowel Project trial R-04. J
Clin Oncol. 32:1927–1934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duffy MJ, Lamerz R, Haglund C, Nicolini A,
Kalousová M, Holubec L and Sturgeon C: Tumor markers in colorectal
cancer, gastric cancer and gastrointestinal stromal cancers:
European group on tumor markers 2014 guidelines update. Int J
Cancer. 134:2513–2522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Itai S, Fujii Y, Nakamura T, Chang YW,
Yanaka M, Saidoh N, Handa S, Suzuki H, Harada H, Yamada S, et al:
Establishment of CMab-43, a sensitive and specific anti-CD133
monoclonal antibody, for immunohistochemistry. Monoclon Antib
Immunodiagn Immunother. 36:231–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ota T, Suzuki Y, Nishikawa T, Otsuki T,
Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, et al:
Complete sequencing and characterization of 21,243 full-length
human cDNAs. Nat Genet. 36:40–45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Otsuki T, Ota T, Nishikawa T, Hayashi K,
Suzuki Y, Yamamoto J, Wakamatsu A, Kimura K, Sakamoto K, Hatano N,
et al: Signal sequence and keyword trap in silico for selection of
full-length human cDNAs encoding secretion or membrane proteins
from oligo-capped cDNA libraries. DNA Res. 12:117–126. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kimura K, Wakamatsu A, Suzuki Y, Ota T,
Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K,
Wakaguri H, et al: Diversification of transcriptional modulation:
Large-scale identification and characterization of putative
alternative promoters of human genes. Genome Res. 16:55–65. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Itoh M, Yasunishi A, Imamura K,
Kanamori-Katayama M, Suzuki H, Suzuki M, Carninci P, Kawai J and
Hayashizaki Y: Constructing ORFeome resources with removable
termination codons. Biotechniques. 41:44–50, 46, 48 passim. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dzobo K, Senthebane DA, Ganz C, Thomford
NE, Wonkam A and Dandara C: Advances in therapeutic targeting of
cancer stem cells within the tumor microenvironment: An updated
review. Cells. 9:18962020. View Article : Google Scholar
|
|
23
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kato Y, Ohishi T, Yamada S, Itai S,
Furusawa Y, Sano M, Nakamura T, Kawada M and Kaneko MK: Anti-CD133
monoclonal antibody CMab-43 exerts antitumor activity in a mouse
xenograft model of colon cancer. Monoclon Antib Immunodiagn
Immunother. 38:75–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takei J, Kaneko MK, Ohishi T, Kawada M,
Harada H and Kato Y: H2Mab-19, an anti-human epidermal
growth factor receptor 2 monoclonal antibody exerts antitumor
activity in mouse oral cancer xenografts. Exp Ther Med. 20:846–853.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kato Y, Ohishi T, Takei J, Nakamura T,
Sano M, Asano T, Sayama Y, Hosono H, Kawada M and Kaneko MK: An
anti-human epidermal growth factor receptor 2 monoclonal antibody
H2Mab-19 exerts antitumor activity in mouse colon cancer
xenografts. Monoclon Antib Immunodiagn Immunother. 39:123–128.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spizzo G, Fong D, Wurm M, Ensinger C,
Obrist P, Hofer C, Mazzoleni G, Gastl G and Went P: EpCAM
expression in primary tumour tissues and metastases: An
immunohistochemical analysis. J Clin Pathol. 64:415–420. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Balzar M, Prins FA, Bakker HA, Fleuren GJ,
Warnaar SO and Litvinov SV: The structural analysis of adhesions
mediated by Ep-CAM. Exp Cell Res. 246:108–121. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liao MY, Lai JK, Kuo MY, Lu RM, Lin CW,
Cheng PC, Liang KH and Wu HC: An anti-EpCAM antibody EpAb2-6 for
the treatment of colon cancer. Oncotarget. 6:24947–24968. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eyvazi S, Farajnia S, Dastmalchi S,
Kanipour F, Zarredar H and Bandehpour M: Antibody Based EpCAM
Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug
Targets. 18:857–868. 2018. View Article : Google Scholar : PubMed/NCBI
|
